Gyre Therapeutics, Inc. (NASDAQ:GYRE)
| Market Cap | 493.06M-41.3% |
| Revenue (ttm) | 121.75M+10.5% |
| Net Income | -25.00M-467.2% |
| EPS | -0.28-4870.7% |
| Shares Out | 106.03M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Jan 13, 2023 |
| Volume | 224,593 |
| Open | 4.80 |
| Previous Close | 4.76 |
| Day's Range | 4.52 - 4.80 |
| 52-Week Range | 3.97 - 9.14 |
| Beta | 4.74 |
| Analysts | Buy |
| Price Target | 17.00(+265.59%) |
| Earnings Date | Mar 11, 2027 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About GYRE
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 11, 2027Earnings report
$GYRE stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in GYRE holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by GYRE's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
GYRE Estimated quarterly lobbying spending
Source: U.S. Senate LDA
GYRE Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| ETUARY | $31.38M | 95.06% |
| Etorel | $983.00K | 2.98% |
| Collaborations | $508.00K | 1.54% |
| Other Products | $81.00K | 0.25% |
| Contiva | $59.00K | 0.18% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New GYRE patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to GYRE from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in GYRE
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $7.64M |
| VXFVanguard Extended Market ETF | $2.94M |
| IWMiShares Russell 2000 ETF | $1.87M |
| SCHASchwab U.S. Small-Cap ETF | $883.13K |
| VTWOVanguard Russell 2000 ETF | $664.19K |
| IWOiShares Russell 2000 Growth ETF | $481.86K |
Estimated from each fund’s disclosed top holdings × AUM
GYRE Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from GYRE’s recent data — informational, not investment advice